GLP-1s before hip replacement: lower complication rates are not a timing rule

Hip-replacement research asks a different question from knee-pain trials

A study of pain and mobility in people with knee osteoarthritis does not establish what happens around a hip replacement. Surgery adds different outcomes: infection, hospital readmission, recovery, medication tolerance and revision. I would keep the operation and study population visible before borrowing a GLP-1 headline for a preoperative decision. Even within hip-replacement research, a lower rate in medical records is not a tested instruction to begin a drug, lose a particular amount of weight or postpone an operation. Those decisions require the surgical and medical teams to consider the person’s full situation. For the separate randomized pain study, see our STEP 9 knee-pain guide.

One semaglutide cohort reported fewer readmissions and infections

A retrospective study of total hip arthroplasty compared semaglutide users with matched nonusers. It reported lower 90-day readmission rates, 6.2% versus 8.8%, and lower prosthetic joint infection rates, 1.6% versus 2.9%. These percentages are observed group outcomes, not guaranteed reductions caused by the drug. Medication users can differ in health, access to care and clinical management even after matching. I would retain the study design in the same sentence as the result rather than converting an association into a preoperative treatment recommendation. The follow-up window also needs to remain attached to each endpoint.^[1]

A second cohort studied a particular obesity group

Another hip-replacement cohort focused on patients described in the paper as having morbid obesity. GLP-1 users had lower observed 90-day infection, readmission and some medical-complication rates than controls. That is relevant to a selected population, but it does not determine an individual patient’s eligibility for surgery or establish a universal BMI threshold. I would ask how the comparison groups were assembled and whether the analysis captured actual medicine use, dose or other aspects of care. A diagnosis code and a prescription record cannot fully describe nutrition, physical function or every factor affecting recovery.^[2]

The smaller clinical study adds a less favorable finding

A separate study matched 66 GLP-1 users undergoing hip replacement with 126 nonusers. Early postoperative nausea and vomiting were recorded more often among users, 18.2% versus 6.0%. It did not find notable differences in length of stay, readmission or the patient-reported hip outcome measures assessed. The sample was small and included several GLP-1 medicines. This does not prove a class-wide harm, but it is a reason to avoid describing the literature as uniformly favorable. Different studies can identify different signals, especially when their settings, medicines and outcome definitions vary.^[3]

Matching is useful but does not recreate randomization

Researchers can match patients using recorded factors such as age, diagnosis or BMI. That improves the comparison without guaranteeing that every relevant difference has been removed. People receiving a GLP-1 might also have different access to follow-up, diabetes care, other prescriptions or preparation for surgery. Some of those differences may not be measured well. I would read the cohort results as associations that help frame future research and clinical questions. They do not tell us what would have happened if the same patient had been randomly assigned to start or avoid the medicine before the operation. The broader distinction is explained in real-world versus trial evidence.

Perioperative medication instructions need a separate plan

Zepbound labeling reports pulmonary aspiration in people using GLP-1 medicines during procedures requiring general anesthesia or deep sedation. A favorable infection association does not cancel that warning or provide a safe hold interval. Tell the surgeon and anesthesia team the exact medication, schedule, recent changes and gastrointestinal symptoms. Ask them to coordinate with the prescriber and give instructions for your operation. Do not copy another patient’s fasting plan or independently skip treatment because a review article discusses delayed stomach emptying. A medication plan must fit the procedure and your medical needs.^[4] Use our anesthesia and procedure-planning checklist to organize the questions before surgery.

Do not let a weight target replace the recovery discussion

If weight management is part of the surgical conversation, ask what the team is trying to improve, how progress will be assessed and how nutrition and function will be protected. A published complication percentage cannot answer those individual questions. I would want the expected benefits of waiting, the disadvantages of delay and the follow-up responsibilities explained together. The research above does not establish that a drug will remove the need for hip replacement or that faster weight loss makes recovery better. Keep the proposed care plan grounded in your clinical evaluation rather than a retrospective association. Ask what information would change the recommendation, so a general discussion of risk becomes a plan with a clear clinical purpose.

Evaluate any added service on its actual responsibilities

If another clinician or online weight-management program is being considered, ask how it will communicate with the surgical team and manage questions before and after the operation. A subscription should not be assumed to include surgical clearance, nutritional assessment or post-discharge monitoring. Compare the fees only after understanding who provides those services. Our provider reviews can help describe appointment and billing models; they cannot establish a lower surgical complication rate for a platform. The useful takeaway is informed coordination, with the evidence and its limits available for your treating teams to discuss. Our Sesame Care review explains an appointment marketplace; verify clinician scope and surgical coordination separately. For the budget, consult the complete GLP-1 costs guide before adding a recurring program.

Continue your research

• Tirzepatide vs semaglutide for A1c: read SURPASS-2 separately from weight-loss trials
• Semaglutide and smoking: craving changes are not proof of quitting
• Semaglutide and NAION: rare vision risk, absolute numbers and urgent symptoms